Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex® in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound

Raymond James Downgrades Dipexium Pharmaceuticals (DPRX) to Market Perform

October 26, 2016 7:33 AM EDT

Raymond James downgraded Dipexium Pharmaceuticals (NASDAQ: DPRX) from Outperform to Market Perform and removed its price target.

For an analyst ratings summary and ratings history on Dipexium Pharmaceuticals click here. For more ratings news on Dipexium Pharmaceuticals click here.

Shares of Dipexium Pharmaceuticals closed at $2.80 yesterday.

... More

Dipexium Pharma (DPRX) Resumes Trading Following LUDP Halt

October 25, 2016 12:35 PM EDT

Dipexium Pharma (NASDAQ: DPRX) resumed trading after LUDP halt. Shares last down 76.5%, versus down 74% prior to halt.

... More

Dipexium Pharma (DPRX) Halted LUDP

October 25, 2016 12:28 PM EDT

Dipexium Pharma (NASDAQ: DPRX) halted LUDP with shares moving off session lows. Shares last down 74%

... More

Feltl & Co Downgrades Dipexium Pharmaceuticals (DPRX) to Hold

October 25, 2016 11:52 AM EDT

Feltl & Co downgraded Dipexium Pharmaceuticals (NASDAQ: DPRX) from Buy to Hold.

For an analyst ratings summary and ratings history on Dipexium Pharmaceuticals click here. For more ratings news on Dipexium Pharmaceuticals click here.

Shares of Dipexium Pharmaceuticals closed at $12.75 yesterday.

... More